Cognition Therapeutics (CGTX) Insider Trading & Ownership $0.43 -0.01 (-2.02%) As of 10:02 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cognition Therapeutics (NASDAQ:CGTX) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage20.75%Number OfInsiders Buying(Last 3 Years)3Amount OfInsider Buying(Last 3 Years)$67,075.00Number OfInsiders Selling(Last 3 Years)0 Get CGTX Insider Trade Alerts Want to know when executives and insiders are buying or selling Cognition Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CGTX Insider Buying and Selling by Quarter Cognition Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails3/14/2024Lisa RicciardiCEOBuy5,700$1.75$9,975.00 11/29/2022Ellen B RichstoneDirectorBuy10,000$2.65$26,500.00 11/15/2022Lisa RicciardiCEOBuy12,000$1.30$15,600.00 11/15/2022Peggy WallaceDirectorBuy12,500$1.20$15,000.00 (Data available from 1/1/2013 forward) CGTX Insider Trading Activity - Frequently Asked Questions Who is on Cognition Therapeutics's Insider Roster? The list of insiders at Cognition Therapeutics includes Ellen B Richstone, Lisa Ricciardi, and Peggy Wallace. Learn more on insiders at CGTX. What percentage of Cognition Therapeutics stock is owned by insiders? 20.75% of Cognition Therapeutics stock is owned by insiders. Learn more on CGTX's insider holdings. Which Cognition Therapeutics insiders have been buying company stock? The following insider purchased CGTX shares in the last 24 months: Lisa Ricciardi ($9,975.00). How much insider buying is happening at Cognition Therapeutics? Insiders have purchased a total of 5,700 CGTX shares in the last 24 months for a total of $9,975.00 bought. Cognition Therapeutics Key ExecutivesMs. Lisa Ricciardi (Age 64)CEO, President & Director Compensation: $854.15kMr. John Brendan Doyle (Age 47)Chief Financial Officer Compensation: $414.88kDr. Anthony O. Caggiano M.D. (Age 54)Ph.D., Chief Medical Officer and Head of R&D Compensation: $616.27kDr. Steven A. Weissman Ph.D.VP & Head of CMC More Insider Trading Tools from MarketBeat Related Companies Coya Therapeutics Insider Buying Vaxart Insider Buying Zentalis Pharmaceuticals Insider Buying Sagimet Biosciences Insider Buying Genelux Insider Buying Zura Bio Insider Buying Atossa Therapeutics Insider Buying Senti Biosciences Insider Buying OptiNose Insider Buying HilleVax Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles McDonald’s Insiders Sell Shares! Investors Should Do the Opposite5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why This page (NASDAQ:CGTX) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.